Interleukin-16

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma (2013) Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR Lung Cancer. 2013 Jun 17. pii: S0169-5002(13)00218-3

Integrative Omics Approach Identifies Interleukin-16 as a Biomarker of Emphysema (2013) Bowler RP, Bahr TM, Hughes G, Lutz S, Kim YI, Coldren CD, Reisdorph N, Kechris KJ OMICS. 2013 Oct 19. [Epub ahead of print]

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma (2012) Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, Shyr Y, Weaver KD, Thompson RC Int J Oncol. 2012 Jun;40(6):1995-2003

Immune Activation in Advanced Cancer Patients Treated with Recombinant IL-21: Multianalyte Profiling of Serum Proteins. (2009) Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD Cancer Immunol Immunother 58: 843-854.

Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. (2008) Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz SM Arthritis Rheum 58: 1465-1474.